CUE · Cue Biopharma, Inc.

Represents the grant of restricted stock units ("RSUs"). The shares subject to the RSU vest in equal quarterly installments over four years from July 13, 2026, subject to the reporting person's continued service with the issuer through each vest date.

The stock option becomes exercisable in equal quarterly installments over four years from July 13, 2026, subject to the reporting person's continued service with the issuer through each vest date.

Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date.

Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date.

Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date.

Represents that grant of restricted stock units ("RSUs"). The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date.

Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration.

Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration.

Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date.

Total holdings held after the transaction reflects a 1-for-30 reverse split of the issuer's stock effected on April 22, 2026.

Represents that grant of restricted stock units ("RSUs"). The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date.

Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration.

Represents that grant of restricted stock units ("RSUs"). The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date.

On April 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026.

The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023.

On April 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026.

The securities do not have an expiration date.

The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023.

The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments.

The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments.

This stock option becomes exercisable in 48 equal monthly installments beginning on April 30, 2026.

This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter.

This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter.

This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter.

Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

This stock option becomes fully exercisable on the first anniversary of the grant date.

Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

This stock option becomes fully exercisable on the first anniversary of the grant date.

Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

This stock option becomes fully exercisable on the first anniversary of the grant date.

Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

This stock option becomes fully exercisable on the first anniversary of the grant date.

Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

This stock option becomes fully exercisable on the first anniversary of the grant date.

Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

This stock option becomes fully exercisable on the first anniversary of the grant date.

On July 24, 2024 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria for these shares was deemed satisfied or waived on December 3, 2025 and these shares underlying the option vested.

This stock option becomes fully exercisable on the first anniversary of the grant date.

This stock option becomes exercisable in 48 monthly installments beginning on September 29, 2026.

This stock option becomes fully exercisable on the first anniversary of the grant date.

On July 24, 2024 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria for these shares was deemed satisfied or waived on September 26, 2025 and these shares underlying the option vested.

Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

This option was granted on June 4, 2025. The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments.

This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025.

This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025.

This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025.

This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025.

This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025.